{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:53:26Z","timestamp":1791395606768,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01317-9","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:10:11Z","timestamp":1791393011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights into Drug Absorption Impairment Mechanisms in Hepatic Impairment using Physiologically-based Pharmacokinetic Modelling: A Case Study with Nilotinib"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8010-9278","authenticated-orcid":false,"given":"Laura G.","family":"Al-Amiry Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-9992","authenticated-orcid":false,"given":"Chara","family":"Litou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-1970","authenticated-orcid":false,"given":"Karen","family":"Rowland Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1317_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijpharm.2017.07.010","volume":"529","author":"M Herbrink","year":"2017","unstructured":"Herbrink M, Schellens JHM, Beijnen JH, et al. Improving the solubility of nilotinib through novel spray-dried solid dispersions. Int J Pharm. 2017;529:294\u2013302.","journal-title":"Int J Pharm"},{"key":"1317_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.xphs.2018.10.032","volume":"108","author":"S Dodd","year":"2019","unstructured":"Dodd S, Kollipara S, Sanchez-Felix M, et al. Prediction of ARA\/PPI drug-drug interactions at the drug discovery and development interface. J Pharm Sci. 2019;108:87\u2013101.","journal-title":"J Pharm Sci"},{"key":"1317_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2010","unstructured":"Tanaka C, Yin OQP, Sethuraman V, et al. Clinical pharmacokinetics of the BCR\u2013ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010;87:197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11095-019-2590-y","volume":"36","author":"NJ Koehl","year":"2019","unstructured":"Koehl NJ, Holm R, Kuentz M, et al. New insights into using lipid based suspensions for \u2018brick dust\u2019 molecules: case study of nilotinib. Pharm Res. 2019;36:56.","journal-title":"Pharm Res"},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.dmpk.2019.08.006","volume":"35","author":"M Sasaki","year":"2020","unstructured":"Sasaki M, Aoyama T, Sugawara M, et al. Influence of gastrointestinal activity on the absorption of nilotinib. Drug Metab Pharmacokinet. 2020;35:102\u201310.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1317_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00228-012-1282-x","volume":"68","author":"A Fujimi","year":"2012","unstructured":"Fujimi A, Takahashi N, Miura M, et al. Bile acid is important for gastrointestinal absorption of nilotinib. Eur J Clin Pharmacol. 2012;68:1575\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"1317_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/cpt.2897","volume":"113","author":"AC Ozbey","year":"2023","unstructured":"Ozbey AC, Bachmann F, Duthaler U, et al. Dose adjustment in patients with liver cirrhosis - comparison of two different modeling approaches. Clin Pharmacol Ther. 2023;113:1346\u201358.","journal-title":"Clin Pharmacol Ther"},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1124\/dmd.109.027466","volume":"37","author":"CD Fisher","year":"2009","unstructured":"Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087\u201394.","journal-title":"Drug Metab Dispos"},{"key":"1317_CR9","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/j.clinthera.2009.11.015","volume":"31","author":"OQP Yin","year":"2009","unstructured":"Yin OQP, Gallagher N, Tanaka C, et al. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009;31:2459\u201369.","journal-title":"Clin Ther"},{"key":"1317_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43258-9","volume":"13","author":"D Gao","year":"2023","unstructured":"Gao D, Wang G, Wu H, et al. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic\/renal impairment. Sci Rep. 2023;13:16027.","journal-title":"Sci Rep"},{"key":"1317_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01468-y","author":"AC Ozbey","year":"2025","unstructured":"Ozbey AC, Meneses-Lorente G, Simmons B, et al. Clinical exploration and physiologically based modelling of the impact of hepatic impairment on entrectinib pharmacokinetics. Clin Pharmacokinet. 2025. https:\/\/doi.org\/10.1007\/s40262-024-01468-y.","journal-title":"Clin Pharmacokinet"},{"key":"1317_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70177","volume":"15","author":"LG Al-Amiry Santos","year":"2026","unstructured":"Al-Amiry Santos LG, Polak S, Yeo KR. Evaluating the impact of intestinal bile salts on drug absorption using PBPK modeling: case studies with efavirenz, cinnarizine, and posaconazole. CPT Pharmacomet Syst Pharmacol. 2026;15:e70177.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1317_CR13","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/cpt.3601","volume":"117","author":"H Qosa","year":"2025","unstructured":"Qosa H, Younis IR, Sahasrabudhe V, et al. Opportunities and challenges of hepatic impairment physiologically based pharmacokinetic modeling in drug development-an IQ perspective. Clin Pharmacol Ther. 2025;117:1682\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"1317_CR14","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s13346-023-01334-7","volume":"13","author":"M Chougule","year":"2023","unstructured":"Chougule M, Sirvi A, Saini V, et al. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach. Drug Deliv Transl Res. 2023;13:2503\u201319.","journal-title":"Drug Deliv Transl Res"},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.2125","volume":"110","author":"T Heimbach","year":"2021","unstructured":"Heimbach T, Chen Y, Chen J, et al. Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2021;110:297\u2013310.","journal-title":"Clin Pharmacol Ther"},{"key":"1317_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225\u201337.","journal-title":"AAPS J"},{"key":"1317_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/bdd.1821","volume":"33","author":"B Xia","year":"2012","unstructured":"Xia B, Heimbach T, He H, et al. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos. 2012;33:536\u201349.","journal-title":"Biopharm Drug Dispos"},{"key":"1317_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0091270010367428","volume":"51","author":"C Tanaka","year":"2011","unstructured":"Tanaka C, Yin OQP, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2011;51:75\u201383.","journal-title":"J Clin Pharmacol"},{"key":"1317_CR19","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1177\/0091270009346061","volume":"50","author":"OQP Yin","year":"2010","unstructured":"Yin OQP, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50:960\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1317_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/psp4.12954","volume":"12","author":"F Salem","year":"2023","unstructured":"Salem F, Nimavardi A, Mudunuru J, et al. Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. CPT Pharmacomet Syst Pharmacol. 2023;12:808\u201320.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1317_CR21","unstructured":"European medicines evaluation agency. Tasigna - Scientific discussion. 2007.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/tasigna-epar-scientific-discussion_en.pdf . Accessed 9 July 2026."},{"key":"1317_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.xphs.2019.01.028","volume":"108","author":"T Heimbach","year":"2019","unstructured":"Heimbach T, Lin W, Hourcade-Potelleret F, et al. Physiologically based pharmacokinetic modeling to supplement nilotinib pharmacokinetics and confirm dose selection in pediatric patients. J Pharm Sci. 2019;108:2191\u20138.","journal-title":"J Pharm Sci"},{"key":"1317_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081169","author":"SK Chirumamilla","year":"2021","unstructured":"Chirumamilla SK, Banala VT, Jamei M, et al. Mechanistic PBPK modelling to predict the advantage of the salt form of a drug when dosed with acid reducing agents. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13081169.","journal-title":"Pharmaceutics"},{"key":"1317_CR24","unstructured":"Novartis Singapore. Tasigna\u00ae (nilotinib) capsules: Singapore prescribing information. 2020."},{"key":"1317_CR25","unstructured":"U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s): tasigna (nilotinib) Capsules, NDA 22\u2013068. 2007.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022068s000_clinpharmr.pdf. Accessed 19 Mar 2026."},{"key":"1317_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189\u2013206.","journal-title":"Clin Pharmacokinet"},{"key":"1317_CR27","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.123.000960","volume":"53","author":"N Isoherranen","year":"2025","unstructured":"Isoherranen N. Physiologically based pharmacokinetic modeling of small molecules: how much progress have we made? Drug Metab Dispos. 2025;53:100013.","journal-title":"Drug Metab Dispos"},{"key":"1317_CR28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, et al. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43:1823\u201337.","journal-title":"Drug Metab Dispos"},{"key":"1317_CR29","doi-asserted-by":"crossref","unstructured":"Mccormick WC, Bell CC, Swell L, et al. Cholic acid synthesis as an index of the severity of liver disease in man. 1973.","DOI":"10.1136\/gut.14.11.895"},{"key":"1317_CR30","unstructured":"Ponz De Leon M, Carulli N, Loria P, Iori R, Zironi F.\u00a0Dietary cholesterol absorption in cirrhosis: the role of total and individual bile acid pool size. Ital J Gastroenterology. 1980;12:221."},{"key":"1317_CR31","doi-asserted-by":"crossref","unstructured":"Miettinen1 TA. Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease. 1972.","DOI":"10.1136\/gut.13.9.682"},{"key":"1317_CR32","doi-asserted-by":"publisher","first-page":"122627","DOI":"10.1016\/j.ijpharm.2023.122627","volume":"634","author":"P \u0160alam\u00fanov\u00e1","year":"2023","unstructured":"\u0160alam\u00fanov\u00e1 P, Krej\u010d\u00ed T, Ry\u0161\u00e1nek P, Salo\u0148 I, Kroupov\u00e1 J, Hubatova-Vackova A, et al. Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os. Int J Pharm. 2023;634:122627.","journal-title":"Int J Pharm."},{"key":"1317_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/psp4.12901","volume":"12","author":"MK Ladumor","year":"2023","unstructured":"Ladumor MK, Storelli F, Liang X, et al. Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT Pharmacomet Syst Pharmacol. 2023;12:261\u201373.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1317_CR34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/HEP.0000000000000521","volume":"81","author":"J Trebicka","year":"2025","unstructured":"Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis. Hepatology. 2025;81:288\u2013303.","journal-title":"Hepatology"},{"key":"1317_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/snep.2001.21666","volume":"21","author":"A C\u00e1rdenas","year":"2001","unstructured":"C\u00e1rdenas A, Gin\u00e8s P. Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis. Semin Nephrol. 2001;21:308\u201316.","journal-title":"Semin Nephrol"},{"key":"1317_CR36","doi-asserted-by":"crossref","unstructured":"Santos LGA-A, Musther H, Bala N, et al. Gastrointestinal bile salt concentrations in healthy adults under fasted and fed conditions: a systematic review and meta-analysis for mechanistic physiologically-based pharmacokinetic (PBPK) modelling. AAPS J. 2025;27:31.","DOI":"10.1208\/s12248-025-01016-x"},{"key":"1317_CR37","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0016-5085(79)90155-0","volume":"77","author":"K von Bergmann","year":"1979","unstructured":"von Bergmann K, Mok HY, Hardison WG, et al. Cholesterol and bile acid metabolism in moderately advanced, stable cirrhosis of the liver. Gastroenterology. 1979;77:1183\u201392.","journal-title":"Gastroenterology"},{"key":"1317_CR38","doi-asserted-by":"crossref","unstructured":"Schwartz CC, Almond HR, Vlahcevic ZR, et al. Bile acid metabolism in cirrhosis. V. Determination of biliary lipid secretion rates in patients with advanced cirrhosis. Gastroenterology. 1979;77:1177\u201382.","DOI":"10.1016\/0016-5085(79)90154-9"},{"key":"1317_CR39","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/jps.24603","volume":"105","author":"D Riethorst","year":"2016","unstructured":"Riethorst D, Mols R, Duchateau G, et al. Characterization of human duodenal fluids in fasted and fed state conditions. J Pharm Sci. 2016;105:673\u201381.","journal-title":"J Pharm Sci"},{"key":"1317_CR40","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jps.21502","volume":"98","author":"S Clarysse","year":"2009","unstructured":"Clarysse S, Tack J, Lammert F, et al. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci. 2009;98:1177\u201392.","journal-title":"J Pharm Sci"},{"key":"1317_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/jps.20553","volume":"95","author":"J Brouwers","year":"2006","unstructured":"Brouwers J, Tack J, Lammert F, et al. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J Pharm Sci. 2006;95:372\u201383.","journal-title":"J Pharm Sci"},{"key":"1317_CR42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1211\/jpp.58.8.0009","volume":"58","author":"MPDLC Moreno","year":"2006","unstructured":"Moreno MPDLC, Oth M, Deferme S, et al. Characterization of fasted\u2010state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol. 2006;58:1079\u201389.","journal-title":"J Pharm Pharmacol"},{"key":"1317_CR43","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1007\/s11095-015-1710-6","volume":"32","author":"C Reppas","year":"2015","unstructured":"Reppas C, Karatza E, Goumas C, et al. Characterization of contents of distal ileum and cecum to which drugs\/drug products are exposed during bioavailability\/bioequivalence studies in healthy adults. Pharm Res. 2015;32:3338\u201349.","journal-title":"Pharm Res"},{"key":"1317_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jphp.12686","volume":"69","author":"T Tran","year":"2017","unstructured":"Tran T, Fatouros DG, Vertzoni M, et al. Mapping the intermediate digestion phases of human healthy intestinal contents from distal ileum and caecum at fasted and fed state conditions. J Pharm Pharmacol. 2017;69:265\u201373.","journal-title":"J Pharm Pharmacol"},{"key":"1317_CR45","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s11095-009-9927-x","volume":"26","author":"A Diakidou","year":"2009","unstructured":"Diakidou A, Vertzoni M, Goumas K, et al. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res. 2009;26:2141\u201351.","journal-title":"Pharm Res"},{"key":"1317_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/j.2040-4603.2020.tb00108.x","volume":"10","author":"AL Ticho","year":"2019","unstructured":"Ticho AL, Malhotra P, Dudeja PK, et al. Intestinal absorption of bile acids in health and disease. Compr Physiol. 2019;10:21\u201356.","journal-title":"Compr Physiol"},{"key":"1317_CR47","doi-asserted-by":"crossref","unstructured":"Vlahcevic ZR, Buhac I, Farrar JT, et al. Bile acid metabolism in patients with cirrhosis: I. Kinetic aspects of cholic acid metabolism. Gastroenterology. 1971;60:491\u20138.","DOI":"10.1016\/S0016-5085(71)80053-7"},{"key":"1317_CR48","first-page":"17","volume":"2","author":"P Davcev","year":"1969","unstructured":"Davcev P, Vanovski B, Sestakov D, et al. Protein-losing enteropathy in patients with liver cirrhosis. Digestion. 1969;2:17\u201322.","journal-title":"Digestion"},{"key":"1317_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3346\/jkms.2004.19.3.466","volume":"19","author":"HL Lee","year":"2004","unstructured":"Lee HL, Han DS, Kim JB, et al. Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report. J Korean Med Sci. 2004;19:466\u20139.","journal-title":"J Korean Med Sci"},{"key":"1317_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ajcn\/19.4.219","volume":"19","author":"FL Iber","year":"1966","unstructured":"Iber FL. Protein loss into the gastrointestinal tract in cirrhosis of the liver. Am J Clin Nutr. 1966;19:219\u201322.","journal-title":"Am J Clin Nutr"},{"key":"1317_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/psp4.12791","volume":"11","author":"U Ezuruike","year":"2022","unstructured":"Ezuruike U, Zhang M, Pansari A, et al. Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator. CPT Pharmacomet Syst Pharmacol. 2022;11:805\u201321.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1317_CR52","unstructured":"European Medicines Agency. Tasigna: EPAR - Scientific discussion. 2007.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/tasigna-epar-scientific-discussion_en.pdf. Accessed 14 July 2025."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01317-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01317-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01317-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:10:14Z","timestamp":1791393014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01317-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01317-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest related to this work. No financial or personal relationships influenced the research presented in this manuscript. All funding sources have been acknowledged appropriately, and the study was conducted independently of any funding body\u2019s influence on the study design, data collection, analysis, or interpretation of results.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"166"}}